About Expedeon
Expedeon is a company based in Swavesey (United Kingdom) founded in 2003 was acquired by Abcam in November 2019. Expedeon has raised $390 thousand across 1 funding round from investors including Abcam, Santander Bank and SYGNIS. The company has 1,587 employees as of December 31, 2021. Expedeon offers products and services including Primary Antibodies, ELISA Kits, and Cell Lines. Expedeon operates in a competitive market with competitors including PrognomiQ, PreOmics, LenioBio, Vivostat and List Biological Laboratories, among others.
- Headquarter Swavesey, United Kingdom
- Employees 1587 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Abcam Limited
- Date of Incorporation 12 Feb, 1998
- Jurisdiction CAMBRIDGE, UNITED KINGDOM
-
Annual Revenue
$636.76 (USD)0as on Dec 31, 2021
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$390 K (USD)
in 1 rounds
-
Latest Funding Round
$390 K (USD), Seed
Sep 22, 2014
-
Investors
Abcam
& 2 more
-
Employee Count
1587
as on Dec 31, 2021
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Expedeon
Expedeon offers a comprehensive portfolio of products and services, including Primary Antibodies, ELISA Kits, and Cell Lines.
Antibodies for detecting proteins in experiments and assays
Kits for measuring specific substances in samples
Gene-edited lines for research in genetics and diseases
Funding Insights of Expedeon
Expedeon has successfully raised a total of $390K through 1 strategic funding round. The most recent funding activity was a Seed round of $390 thousand completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Expedeon
Expedeon has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Abcam, Santander Bank and SYGNIS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Commercial banking services are offered in the United States.
|
Locked | Locked | Locked | |
|
Biological reagents and antibodies are developed for life science research.
|
Locked | Locked | Locked | |
|
SYGNIS provides molecular biology reagents for research and laboratory applications.
|
Locked | Locked | Locked |
Investor details for Expedeon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Expedeon
Investment portfolio details for Expedeon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Expedeon
Detailed financials for Expedeon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Expedeon Comparisons
Peer comparison for Expedeon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Expedeon
Expedeon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PrognomiQ, PreOmics, LenioBio, Vivostat and List Biological Laboratories, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of tests for the detection and treatment of cancer and other diseases
|
|
| Locked | Locked | Locked |
Reagents and instruments for proteomics research are supplied by PreOmics.
|
|
| Locked | Locked | Locked |
Kits for cell-free eukaryotic protein expression are provided.
|
|
| Locked | Locked | Locked |
On-site fibrin sealant preparation systems are developed and provided.
|
|
| Locked | Locked | Locked |
Specializes in the production of research reagents
|
Detailed competitors of Expedeon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Expedeon
Complete news archive for Expedeon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Expedeon
Expedeon was founded in 2003 and raised its 1st funding round 11 years after it was founded.
Expedeon is headquartered in Swavesey, United Kingdom. It is registered at Swavesey, Cambridgeshire, United Kingdom.
Expedeon is a funded company, having raised a total of $390K across 1 funding round to date.
As of Dec 31, 2021, the latest employee count at Expedeon is 1,587.
Annual revenue of Expedeon is $636.76 as on Dec 31, 2021.
Expedeon was founded in 2003 in Swavesey, United Kingdom, and operates within the biotechnology sector focused on protein research. Solutions are provided for protein electrophoresis, proteomics, structural biology, protein purification, quantification, Western blotting, sample preparation, and cell signaling. Products such as gels, primers, stains, and antibodies are offered to support these applications in research settings.
Expedeon offers Primary Antibodies, ELISA Kits, and Cell Lines.
Expedeon has 3 investors. Key investors include Abcam, Santander Bank, and SYGNIS.